Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xbrane Data Sets Up EU And US Ranibizumab Filings

Filing Dates Confirmed For Xlucane Biosimilar Of Lucentis After Phase III Results

Executive Summary

Hot on the heels of Samsung Bioepis receiving an EMA endorsement for its Byooviz version, Xbrane Biopharma has laid out plans for its own ranibizumab biosimilar, Xlucane, to be filed in both the EU and the US following positive Phase III results.

You may also be interested in...



Xbrane And Stada Celebrate Major Milestone With EU Filing For Lucentis Rival

Xbrane Biopharma has taken a key step on its journey to begin generating cash from operations by early 2024 at the latest, after its Xlucane biosimilar ranibizumab asset was submitted to the European Medicines Agency by co-development and commercialization partner Stada.

US Lucentis Competition Expectations Upended By Byooviz

Samsung Bioepis’ indication that it will not launch its FDA-approved ranibizumab biosimilar, Byooviz, before June 2022 has changed what we know about the competitive landscape for Lucentis in the US.

Teva Brings In Ranibizumab Biosimilar As Bioeq Files In Europe

Biosimilar Lucentis in Europe is once again in the headlines, as Teva announced a deal to in-license Bioeq and Formycon’s FYB201 ranibizumab candidate in several key global markets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151037

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel